Mydrane (Lidocaine Hydrochloride Monohydrate, Phenylephrine Hydrochloride, Tropicamide)

Lidocaine blocks voltage‑gated sodium channels, producing local anesthesia. Phenylephrine stimulates α1‑adrenergic receptors on the dilator pupillae muscle, causing contraction and pupil widening. Tropicamide blocks muscarinic receptors in the sphincter pupillae, preventing constriction. Together they achieve swift mydriasis and analgesia within the anterior chamber.

The dose of Mydrane is determined by the operating ophthalmologist based on the specific surgical protocol and patient characteristics. It is supplied as a ready‑to‑use intracameral solution, and the prescriber decides the volume to inject at the time of surgery.

Safety data for Mydrane in pregnancy and lactation are limited. Because the product is administered directly into the eye, systemic exposure is minimal, but the decision to use it should be made by the treating physician after weighing potential benefits and risks for the mother and fetus or infant.

To order Mydrane, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Mydrane combines a local anesthetic (lidocaine) with two mydriatics (phenylephrine and tropicamide) in a single intracameral injection, offering both analgesia and dilation. Compared with separate topical drops, Mydrane provides faster, more consistent pupil dilation and eliminates the need for multiple applications, which can improve surgical efficiency and patient comfort.

Mydrane should be stored at 2‑8 °C, protected from light, and kept in its original sealed container. Do not freeze or shake the vial. Before use, allow the solution to reach room temperature if required by the surgical protocol, and inspect for any particulate matter or discoloration.

Mydrane is administered by the surgeon as an intracameral injection directly into the anterior chamber of the eye at the start of the procedure. The sterile solution is delivered using a fine‑gauge cannula, and the volume injected is determined by the operative plan and patient response.

Serious risks, though rare, include severe allergic reactions (anaphylaxis), sustained elevation of intra‑ocular pressure, persistent mydriasis, corneal endothelial toxicity, and endophthalmitis. Surgeons should monitor patients closely for signs of these events and be prepared to manage them promptly if they occur.

Mydrane should be avoided in patients with known hypersensitivity to lidocaine, phenylephrine, tropicamide or any excipients, in eyes with active corneal disease, and in individuals with uncontrolled hypertension or severe cardiovascular disease unless the benefits outweigh the risks. Pediatric use is generally not recommended unless specifically indicated by an ophthalmologist.